Conference Series

Protected: Dr. Pedro Rosa-Neto; June 21st, 2017 – 52nd CSFN

AAIC 2017 London:

  • Elevated CSF levels of neurofilament light chain is associated with gray matter neurodegeneration in both humans and transgenic rat model of Alzheimer’s disease

– Monica Shin, MSc


  • PET tau and amyloid synergy in default mode network determines clinical status in early phases of Alzheimer’s disease.

    Global and regional amyloid independently impair the DMN leading to cognitive decline

  • Voxel-wise determination of sensitivity, specificity, and thresholds for amyloid positivity using [18F]Florbetapir PET

  • Voxel-based power calculation and thresholds predictive of imminent neurodegeneration for preclinical Alzheimer’s disease clinical trials

– Tharick A. Pascoal, MD


  • Interaction between NEFL and APOE genes confers vulnerability to neurodegeneration

– Andrea L. Benedet, MSc


  • FDG-PET power to predict memory decline in Alzheimer’s disease depends on disease phase and amyloid and tau status

– Hanne Struyfs, MSc


  • Graph-Theory analysis shows a highly efficient but redundant network in MCI TAU propagation

– Sulantha Mathotaarachchi, MSc


  • Amyloid-Beta Modulates Cerebral Metabolic Network in Rats and Humans

  • Preclinical Assessment of Kal-ABP Target Engagement and Efficacy Using PET, MRI and CSF Biomarkers

– Min Su Kang, BSc


  • In vivo and in vitro demonstration of [18F]THK5351 binding to monoamine oxidase–B in the human brain

– Kok Pin Ng, MRCP